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Cooperation between thymic-derived cells (T cells) and bone marrow-derived pre- 
cursors of antibody-forming cells (B cells) is not thought to be required for an anti- 
body  response  to  Type  III pneumococcal polysaccharide,  or  SSS-III  1 (1-3).  Yet 
treatment with antilymphocyte or antithymocyte serum (ALS or ATS), which causes 
a depletion of T  cells (4-10), produces a significant increase in the magnitude of both 
the plaque-forming cell (PFC) and the serum antibody  response to this antigen (11-14) 
and an increase in the serum antibody response to keyhole limpet hemocyanin (15) 
and polyvinylpyrolidone (16).  With respect to  the  PFC response to  SSS-III, such 
enhancement can be abrogated by the infusion of  syngeneic thymocytes; however, 
the infusion of peripheral white blood cells, a population reported to contain 60-90% 
T  cells (17, 18), results in additional enhancement (12). 
On the basis of these findings, we hypothesized that two functionally distinct types 
of cells (suppressor and amplifier cells2), presumably both thymic-derived, act in an 
opposing manner to regulate the magnitude of the antibody response to SSS-III by 
B  cells;  the enhancement produced after treatment with either ALS  or ATS is ap- 
parently due to the inactivation of cells that normally exert a  negative, rather than 
a positive, influence on the magnitude of the antibody response elicited after immuni- 
zation (12). 
* This work was supported in part by Research Grant AI 10384-62 and Career Develop- 
ment Award AI 70208-01 from the National Institute of Allergy and Infectious Diseases. 
1 Abbre~.ations used 4n  this paper: ALS,  anfilymphocyte  serum;  ATS,  antithymocyte 
serum; HRBC, horse erythrocytes; PFC, plaque-forming cell(s); SRBC, sheep erythrocytes; 
SSS-III, Type III pneumococcal polysaccharide. 
2 The term "amplifier cell" is used in this report  to distinguish between T  cells that are 
required for  the  development of an antibody response to  some antigens, e.g., "helper"  T 
cells involved in the antibody response to sheep erythrocytes (SRBC) (19), and those types 
of cells which, although not required for the establishment of an antibody response, are cap- 
able of augmenting the magnitude of the response of antigen-stimulated B cells. The mecha- 
nism by which both types of cells produce their effects is not known. 
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The object of the work here reported was to provide more definitive informa- 
tion  on  the  origin and  nature  of such  regulatory  cells.  This  was  accomplished 
by examining the effects of treatment  with ALS on the magnitude of the PFC 
response  to  SSS-III  in  congenitally  athymic  mice,  i.e.,  mice  homozygous  for 
the  autosomal  recessive  mutation  "nude"  (nu/nu  mice);  phenotypically  nor- 
mal littermates  that  were either heterozygous  or homozygous for the presence 
of  thymus  (nu/+  or  +/+,  respectively)  served  as  controls.  The  results  of 
such  studies  showed  that,  while  nude  mice  gave  a  PFC  response  to  SSS-III 
greater than that produced by thymus-bearing control mice, significant enhance- 
ment  was  demonstrable  only  in  the  case  of  control  mice  treated  with  ALS. 
These findings are consistent with the view that  both  suppressor  and amplifier 
cells represent  subpopulations  of  T  cells present  in  thymus-bearing  mice,  but 
absent  in  nude  mice. 
Materials and Methods 
Animals.--Congenitally  athymic  nude  mice  (nu/nu  mice)  and  phenotypically  normal 
littermate controls, i.e., mice heterozygous or homozsgous for the presence of thymus (nu/+ 
or  +/+,  respectively), were derived by a  previously described procedure  (20);  these mice 
were bred and maintained at the Department of Botany and  Microbiology, Montana  State 
University, Bozeman, Mont. Pertinent information concerning the lack of thymic tissue and 
normal immunological functions in nude mice have been reported (20  26). Mice 8-12 wk old, 
of both sexes, were used. 
Female BALB/cAnN mice,  8-/0  wk  old,  were  obtained  from  the  Rodent  and  Rabbit 
Production Unit of the National Institutes of Health, Bethesda, Md. These mice, which are 
normal with respect  to the presence of thymus and  thymic function,  were used in only one 
experiment described in this study (Table II). 
Antigens and Immunization  Procedure.  The  immunological properties  of  the  Type  III 
pneumococcal polysaecharide (SSS-III) used  and the method by which it was prepared have 
been  described  (27~0).  Mice were  given a  single  intraperitoneal  injection of an optimally 
immunogenie dose  (0.5  #g)  of SSS-III in 0.5  ml saline; the magnitude of the antibody re- 
sponse was assessed  at peak, 5 days later. 
Horse erythrocytes (HRBC) were obtained from the Ungulate Unit of the Animal Center 
Section, National Institutes of Health. Mice were given a  single  intraperitoneal injection of 
0.2 ml of a  10% suspension  (vol/vol) of washed HRBC in saline; the magnitude of the anti- 
body response  was assessed  5 days later. 
Detection of A ntibody-Producing or Plaque-Forming Cells.--Splenic PFC  specific  for SSS- 
III were detected by the technique of localized  hemolysis-in-gel (27, 28) ; sheep erythrocytes 
(SRBC)  sensitized  with  SSS-III  by  the  chromium  chloride  coupling  procedure  (31) were 
used as indicator cells. 
PFC specific  for  HRBC were detected  by the same method,  except that native washed 
HRBC  were used as  indicator  cells.  Only  values for direct  3'M-producing  PFC were  con- 
sidered in this work. 
Antilymphocyte Serum.--Horse  antimouse  lymphocyte  serum  (ALS),  lot  13162,  was 
purchased from Microbiological Associates,  Inc.,  Bethesda,  Md. ALS was given as a  single 
intraperitoneal injection at the time of immunization with SSS-III; the amounts of ALS used 
are given at appropriate places in the text. Data supplied by the manufacturer indicate that 
the mean survival time for DBA mouse skin grafts applied to C57BL/6 mice was  increased 
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Statistics,--Student's  t test  (32) was used to evaluate the significance of the differences 
observed. Differences were considered to be significant when probability (P)  values <0.05 
were obtained. 
RESULTS 
Effect of Treatment with ALS on the Magnitude oJ the PFC Response to SSS-III 
in Nude and Littermate Control Mice.--The data of Table I  show that, without 
ALS treatment,  the 5-day PFC response to an optimally immunogenic dose of 
SSS-III was slightly, but significantly, higher (1.6-fold)  in nude mice than in 
thymus-bearing littermate  controls (P  <  0.02); in other studies both groups 
of  mice produced  similar  numbers  of facilitated  7M-producing PFC  in  re- 
sponse to the same dose of  antigen  (33).  Treatment  with  0.3  ml  of ALS had 
no effect on the magnitude of the PFC response of nude mice (P >  0.05). How- 
TABLE I 
Effect of Treatment with ALS on the Magnitude of the PFC Response to SSS-III in Nude and 
Littermate Control Mice 
Treatment of mice 
SSS-III-specifie  PFC/spleen* 
Nude mice  Littermate  controls 
0.5/zg SSS-III 
0.5 #g SSS-III 
+ 
0.3 ml ALS 
3.537 4-  0.0435  3.331 4- 0.049 
(3,440) §  (2,140) 
3.603 -4- 0.123  5.522 4-  0.096 
(4,020)  (333,000) 
* Numbers of PFC detected 5 days after immunization with SSS-III. 
LOgl0 4- standard error of the mean for 8-12 similarly treated mice. 
§ Geometric mean. 
ever, the same amount of ALS produced considerable enhancement (150-fold) 
when given to thymus-bearing littermate  controls (P  <  0.001). 
To determine whether nude and littermate  control mice differ  greatly with 
respect to the amount of ALS required  to produce enhancement, both groups 
of mice were treated with various doses (0.01 ml-0.5 ml) of ALS; the magnitude 
of the PFC response to 0.5/~g of SSS-III was assessed  5 days after immuniza- 
tion. The data of Fig.  1 show that for littermate  control mice, significant en- 
hancement was demonstrable with  all  doses of ALS used; such enhancement 
was ALS dose-dependent and maximal with 0.3  ml of ALS. In contrast, none 
of the tested doses of ALS produced enhancement in nude mice. 
Overt signs  of cytotoxicity were noted only for groups of mice treated with 
the largest dose of ALS used in this study (0.5 rnl).  Both nude and littermate 
control mice became noticeably ill after treatment with this dose and gave PFC 
responses lower than those obtained with 0.3 ml of ALS. Nevertheless, the PFC 
response for control mice given 0.5 ml of ALS was still  significantly higher than 
that of mice not treated with ALS. 1434  REGULATORY  CELLS 
Effect of Trealment with ALS on the Magsitude of the PFC Response to SSS-IH 
and HRBC.--Conventionally  reared  thymus-bearing  BALB/c mice  were  im- 
munized  with  (a)  0.5  t~g of SSS-III,  (b)  0.2  ml  of  10%  HRBC,  or  (c)  both 
antigens  given together; one group of mice immunized with  both antigens re- 
ceived a single injection of 0.3 ml of ALS. The magnitude of the PFC response 
to each immunizing antigen  was assessed  5  days later. 
The data  of Table II show that  the  administration  of HRBC  to non-ALS- 
treated  mice produced no significant change in the magnitude of the PFC re- 
sponse  to  SSS-III (P  >  0.05);  similarly,  immunization  with  SSS-III had  no 
effect  on  the  numbers  of  HRBC-specific  PFC  detected.  However,  for  mice 
given SSS-III and HRBC together, treatment with ALS reduced the magnitude 
of the PFC response to HRBC by about 50%  (P  <  0.01);  the same mice ex- 
hibited about a 20-fold increase in SSS-III-specific PFC (P <  0.001). In other 
studies, three injections of ALS were found to produce almost complete suppres- 
sion  of  the  antibody  response  to  SRBC  (34);  however,  the  same  regimen-- 
using  the  same  preparation  of ALS--gave 8-  to  10-fold  enhancement  of  the 
antibody response  to SSS-III (11,  12).  These findings illustrate  that enhance- 
ment of the antibody response  to SSS-III is demonstrable under conditions in 
which "helper" T  cells, required for an antibody response to SRBC or HRBC, 
are  inactivated  by  treatment  with  ALS. 
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Fro.  1.  Effect of administering different doses of ALS on the magnitude of the 5-day PFC 
response to 0.5/zg of SSS-III in nude and littermate  control mice. Solid and broken horizontal 
lines represent the mean :J= standard  error of the mean, respectively, for mice not given ALS. 
Pooled spleen cell suspensions from five similarly treated mice were used for all determinations. 
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TABLE  II 
Effect of Treatment with ALS  on the Magnitude of the PFC Response to SSS-III and HRBC 
in BA LB/c Mice 
Treatment o[ mice 
PFC/spleen* 
SSS-III specific  HRBC specific 
0.5/~g SSS-III  4.230  ±  0.0605  None detected 
(16,987) § 
0.2 ml 10% HRBC  None detected  4.552  -4-  0.054 
(35,685) 
0.5/zg SSS-III  4.206  i  0.048  4.492  ~  0.063 
+ 
0.2 ml 10% HRBC  (16,079)  (31,013) 
0.5 #g SSS-III  5.494  :~  0.053  4.216  :t:  0.048 
+ 
0.2 ml 10% HRBC  (311,608)  (16,429) 
+ 
0.3 ml ALS 
* Numbers of PFC detected 5 days after immunization. 
:~ Log10 4- standard error of the mean for five similarly treated mice. 
§ Geometric mean. 
DISCUSSION 
Treatment with several other preparations of ALS or ATS has been shown 
to produce a significant increase in the magnitude of the antibody response to 
SSS-III  in  different strains  of inbred  and  hybrid mice  (14).  Nonimmunized 
mice given various amounts of ALS or ATS fail to produce antibody specific 
for SSS-III (unpublished observations). These findings affirm that the ability 
of ALS to enhance the antibody response to SSS-III is a general phenomenon. 
Furthermore, the results of recent studies show that enhancement of the "},M 
antibody response to SSS-III is also accompanied by a  corresponding increase 
in both ~,G and ~/A antibody (to be published) ; enhancement, therefore, cannot 
be attributed to either a  reversal or an alteration of antibody-mediated feed- 
back inhibition (35). 
The present work was conducted primarily to obtain information concerning 
the types of cells involved in mediating ALS-induced enhancement. This was 
accomplished  by  comparing  the  effects of  treatment  with  various  doses  of 
ALS on the magnitude of the ~M PFC response to SSS-III in athymic nude and 
thymus-bearing  littermate  control mice.  The  results  obtained  show  that  all 
doses of ALS employed gave significant enhancement in thymus-bearing mice; 
such enhancement was ALS dose-dependent (Fig. 1). In contrast, no enhance- 
ment was produced in nude mice over the same range of test doses. Since the 
ability  of ALS  to  induce  enhancement  can  be  removed by  adsorption  with 
mouse thymocytes (11,  12),  these  findings  clearly establish  that (a)  thymic- 
derived lymphocytes (T cells)  are  required  to  obtain  ALS-induced enhance- 1436  REGULATORY  CELLS 
ment, and (b) enhancement is not the result of a stinmlatory effect of ALS upon 
B  cells. 
At least three possible mechanisms might account for ALS-induced enhance- 
ment.  In  all  instances it  is  assumed  that  ALS  acts  directly upon  T  cells to 
produce  the  effects described: 
First,  ALS-induced enhancement may be solely the result of a stimulatory 
effect of ALS upon T  cells, and is similar to the type of enhancement produced 
after the administration  of allogeneic cells  (36,  37). This appears to be quite 
unlikely for a number of reasons.  The well-known immunosuppressive effects 
of ALS  have  been  attributed  largely  to  an  extensive depletion  of not  only 
circulating T  cells but also thymic-dependent areas of lymphoid organs (4-10); 
yet ALS-induced enhancement of the antibody response to SSS-III is demon- 
strable under conditions in which there is an almost complete (34), or a  sub- 
stantial, loss (Table II) in the capacity to make antibody specific for "helper" 
T  cell-dependent antigens. Also,  this mechanism fails to account for the fact 
that  ALS-induced enhancement can  be  abrogated by the infusion of normal 
syngeneic thymocytes (12). 
Second, enhancement may be solely the result of the inactivation of T  cells 
that have been reported to exert a negative influence on the magnitude of the 
antibody response  (38-45).  According to such  a  view,  the  magnitude  of the 
antibody response to SSS-III in athymic nude mice, as well  as in neonatally or 
adult  thymectomized mice,  should  be much  greater  than  that  produced  by 
intact normal mice, and similar--if  not  identical--to  that of thynms-bearing 
mice  treated  with ALS; this does not  occur (1-3,  33).  Instead,  the  PFC  re- 
sponse to SSS-III in athymic mice is only 1/100 of that produced by thymus- 
bearing littermate controls given an optimal dose of ALS (Fig.  1)  and is only 
slightly greater than that of non-ALS-treated controls (Table I). The preceding 
findings also argue against a mechanism in which enhancement is due merely 
to T  cell depletion and the creation of additional  "metabolic space," thereby 
permitting a greater expansion of populations of B  cells  (46). 
In view of  the  foregoing considerations,  the  following model  provides  the 
best  explanation for ALS-induced enhancement; it is  in  complete agreement 
with all of the observations cited above. Nude mice lack a population of T cells 
that  normally exert a  negative  influence on  the  magnitude  of  the  antibody 
response to SSS-III; the absence of such suppressor T  cells permits nude mice 
to give an antibody response slightly greater than that produced by thymus- 
bearing mice (Table I). However, the lack of suppressor T  cells per se does not 
nearly permit nude mice to give a response comparable with that produced by 
thymus-bearing controls treated with ALS (Table I; Fig.  l). One must there- 
fore postulate  that  nude  mice  also  lack  an  additional  population  of T  cells 
capable  of  increasing  the  magnitude  of  the  antibody  response  of  antigen- 
stimulated B cells; these have been termed amplifier T cells (12). Thus SSS-III, 
which does not appear to require cooperation between "helper" T  cells and B 
cells to elicit a normal antibody response (1, 3), is not truly a "thymic-independ- BAKER,  REED,  STASHAK,  AMSBAUGH~ AND  PRESCOTT  1437 
ent" antigen, since the magnitude of its antibody response is influenced by the 
activities  of  at  least  two  functionally distinct  types  of  regulatory  T  cells; 
most likely, soluble products released from such cells are responsible for mediat- 
ing their effects (37).  Furthermore, the results of these and  of other studies 
(Table II; 11, 34) suggest that the activities of "helper" T  cells and regulatory 
T cells are independent of one another and are mediated by different subpopula- 
tions of T  cells.  This is contrary to the views of others who propose that the 
product(s)  of a  single, rather than more than one, type of T  cell can--under 
certain circumstances that are still to be defined--exert either a positive or a 
negative influence on the magnitude of the immune response (48). 
It should be noted that the model proposed in this work does not necessarily 
imply that the activities of amplifier and suppressor T cells are always counter- 
balanced.  In  the  normal  antibody  response  to  some  antigens,  e.g.,  SRBC, 
amplifier rather than suppressor cells may play a more dominant role; in this 
case,  treatment  with  ALS  would  result  in  suppression.  For  other  antigens, 
e.g.  SSS-III,  the  converse situation  may apply,  and  enhancement would  be 
obtained. Alternatively, both types of regulatory cells could differ significantly 
with  respect to  tissue  distribution  and  access to ALS, minimal  numbers re- 
quired to produce an effect, and the density or type of surface antigens present. 
Such differences between subpopulations of T  cells have already been described 
(49,  50), and could determine the ease with which amplifier and suppressor T 
cells are inactivated by ALS. Also, amplifier and suppressor T  cells may not 
necessarily  act  at  the  same  level  of  control  for  the  immune  response.  The 
results of current studies indicate that suppressor cells appear to regulate the 
proliferation of antibody-forming B cells (to be published). Although the mode 
of action of amplifier cells is less clear at this point, it is conceivable that such 
cells could act primarily by increasing the rate of antibody synthesis by B cells 
that would otherwise be only minimally stimulated by contact with  antigen 
alone. Either or both types of control processes would have a  decisive effect 
upon the magnitude of the antibody response. These issues are now being in- 
vestigated. 
SUMMARY 
The effect of treatment with antilymphocyte serum (ALS) on the magnitude 
of the  plaque-forming cell  (PFC)  response  to Type III  pneumococcal poly- 
saccharide  (SSS-III)  was assessed in athymic nude mice and thymus-bearing 
littermate controls. Without ALS  treatment,  the  PFC  response was  slightly 
higher in nude than in control mice. Treatment with ALS had no effect on the 
response  of  nude  mice;  however,  considerable  enhancement  was  noted  in 
thymus-bearing  controls.  Such  enhancement  was  ALS  dose-dependent  and 
demonstrable under conditions in which there was substantial inactivation of 
thymic-derived "helper" cells required for an antibody response to erythrocyte 
antigens. 
These findings suggest that amplifier and suppressor cells,  which have been 1438  REGULATORY  CELLS 
reported  to  regulate  the  magnitude  of  the  antibody  response  to  SSS-III, 
represent  populations  of thymic-derived cells  (T cells)  that are not present in 
nude mice. The activities of "helper" T  cells and regulatory T  cells appear to 
be independent  of one another and mediated  by separate  subpopulations of T 
cells. 
The authors  express their  appreciation  to/VIs. Judith K.  Manning  for her  excellent as- 
sistance in performing these studies. 
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